AU2021255613A1 - Methods for preparing tyrosine receptor kinase inhibitors - Google Patents
Methods for preparing tyrosine receptor kinase inhibitors Download PDFInfo
- Publication number
- AU2021255613A1 AU2021255613A1 AU2021255613A AU2021255613A AU2021255613A1 AU 2021255613 A1 AU2021255613 A1 AU 2021255613A1 AU 2021255613 A AU2021255613 A AU 2021255613A AU 2021255613 A AU2021255613 A AU 2021255613A AU 2021255613 A1 AU2021255613 A1 AU 2021255613A1
- Authority
- AU
- Australia
- Prior art keywords
- alkyl
- compound
- formula
- haloalkyl
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063010108P | 2020-04-15 | 2020-04-15 | |
| US63/010,108 | 2020-04-15 | ||
| PCT/US2021/027538 WO2021211882A1 (en) | 2020-04-15 | 2021-04-15 | Methods for preparing tyrosine receptor kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2021255613A1 true AU2021255613A1 (en) | 2022-09-29 |
Family
ID=78083713
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021255613A Pending AU2021255613A1 (en) | 2020-04-15 | 2021-04-15 | Methods for preparing tyrosine receptor kinase inhibitors |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12606565B2 (https=) |
| EP (1) | EP4135700A4 (https=) |
| JP (1) | JP7767301B2 (https=) |
| KR (1) | KR20230011912A (https=) |
| CN (1) | CN115515591B (https=) |
| AU (1) | AU2021255613A1 (https=) |
| BR (1) | BR112022020114A2 (https=) |
| CA (1) | CA3172681A1 (https=) |
| IL (1) | IL296921A (https=) |
| MX (1) | MX2022012437A (https=) |
| WO (1) | WO2021211882A1 (https=) |
| ZA (1) | ZA202209792B (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11739096B2 (en) | 2017-12-15 | 2023-08-29 | Pyramid Biosciences, Inc. | 5-(2,5-difluorophenyl)pyrrolidin-1-yl)-3-(1H-pyrazol-1-yl)pyrazolo [1,5-A]pyrimidine derivatives and related compounds as Trk kinase inhibitors for treating cancer |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL296921A (en) | 2020-04-15 | 2022-12-01 | Pyramid Biosciences Inc | Methods for making receptor tyrosine kinase inhibitors |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| JP2594486B2 (ja) | 1991-01-15 | 1997-03-26 | アルコン ラボラトリーズ インコーポレイテッド | 局所的眼薬組成物 |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| CN101242844A (zh) * | 2005-06-10 | 2008-08-13 | 詹森药业有限公司 | 作为激酶调节剂的氨基嘧啶类化合物 |
| UA95244C2 (ru) * | 2005-06-22 | 2011-07-25 | Плексикон, Инк. | Соединения и способ модулирования активности киназ, и показания для их применения |
| WO2008037477A1 (en) | 2006-09-29 | 2008-04-03 | Novartis Ag | Pyrazolopyrimidines as p13k lipid kinase inhibitors |
| KR101324804B1 (ko) | 2008-05-13 | 2013-11-01 | 아이알엠 엘엘씨 | 키나제 억제제로서의 질소 함유 융합 헤테로사이클 및 그의 조성물 |
| MY169791A (en) | 2008-10-22 | 2019-05-15 | Array Biopharma Inc | Substituted pyrazolo [1,5-a] pyrimidine compounds as trk kinase inhibitors |
| EP2348860B1 (en) | 2008-10-31 | 2015-05-27 | Genentech, Inc. | Pyrazolopyrimidine jak inhibitor compounds and methods |
| WO2012022045A1 (en) * | 2010-08-20 | 2012-02-23 | Hutchison Medipharma Limited | Pyrrolopyrimidine compounds and uses thereof |
| EP3812387A1 (en) | 2011-07-21 | 2021-04-28 | Sumitomo Dainippon Pharma Oncology, Inc. | Heterocyclic protein kinase inhibitors |
| WO2014055928A2 (en) * | 2012-10-04 | 2014-04-10 | University Of Utah Research Foundation | Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors |
| FR3029769A1 (fr) | 2014-12-10 | 2016-06-17 | Tornier Sa | Kit pour une prothese d'epaule |
| CA2971024C (en) | 2014-12-15 | 2023-09-26 | Handok Inc. | Fused ring heteroaryl compounds and their use as trk inhibitors |
| AR103297A1 (es) | 2014-12-30 | 2017-05-03 | Forma Therapeutics Inc | Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 específica de ubiquitina |
| JP6475084B2 (ja) | 2015-05-21 | 2019-02-27 | 臼井国際産業株式会社 | トルクセンサ用シャフトの製造設備およびその製造方法 |
| WO2018005533A1 (en) * | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Antiproliferative pyrimidine-based compounds |
| SG11202005237SA (en) * | 2017-12-15 | 2020-07-29 | Pyramid Biosciences Inc | 5-(2-(2,5-difluorophenyl)pyrrolidin-1 -yl)-3-(1h-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as trk kinase inhibitors for treating cancer |
| IL296921A (en) | 2020-04-15 | 2022-12-01 | Pyramid Biosciences Inc | Methods for making receptor tyrosine kinase inhibitors |
-
2021
- 2021-04-15 IL IL296921A patent/IL296921A/en unknown
- 2021-04-15 CN CN202180024618.XA patent/CN115515591B/zh active Active
- 2021-04-15 CA CA3172681A patent/CA3172681A1/en active Pending
- 2021-04-15 WO PCT/US2021/027538 patent/WO2021211882A1/en not_active Ceased
- 2021-04-15 JP JP2022559980A patent/JP7767301B2/ja active Active
- 2021-04-15 KR KR1020227033977A patent/KR20230011912A/ko active Pending
- 2021-04-15 EP EP21787908.9A patent/EP4135700A4/en active Pending
- 2021-04-15 AU AU2021255613A patent/AU2021255613A1/en active Pending
- 2021-04-15 MX MX2022012437A patent/MX2022012437A/es unknown
- 2021-04-15 BR BR112022020114A patent/BR112022020114A2/pt unknown
- 2021-04-15 US US17/918,880 patent/US12606565B2/en active Active
-
2022
- 2022-09-01 ZA ZA2022/09792A patent/ZA202209792B/en unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11739096B2 (en) | 2017-12-15 | 2023-08-29 | Pyramid Biosciences, Inc. | 5-(2,5-difluorophenyl)pyrrolidin-1-yl)-3-(1H-pyrazol-1-yl)pyrazolo [1,5-A]pyrimidine derivatives and related compounds as Trk kinase inhibitors for treating cancer |
| US12486276B2 (en) | 2017-12-15 | 2025-12-02 | Pyramid Biosciences, Inc. | 5-(2,5-difluorophenyl)pyrrolidin-1-yl)-3-(1H-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as Trk kinase inhibitors for treating cancer |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3172681A1 (en) | 2021-10-21 |
| WO2021211882A1 (en) | 2021-10-21 |
| EP4135700A4 (en) | 2024-04-17 |
| KR20230011912A (ko) | 2023-01-25 |
| US12606565B2 (en) | 2026-04-21 |
| US20230242536A1 (en) | 2023-08-03 |
| JP2023522841A (ja) | 2023-06-01 |
| JP7767301B2 (ja) | 2025-11-11 |
| CN115515591A (zh) | 2022-12-23 |
| EP4135700A1 (en) | 2023-02-22 |
| IL296921A (en) | 2022-12-01 |
| MX2022012437A (es) | 2022-10-27 |
| CN115515591B (zh) | 2024-09-27 |
| BR112022020114A2 (pt) | 2022-11-29 |
| ZA202209792B (en) | 2025-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2022202494B2 (en) | Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof | |
| AU2017376629B2 (en) | Benzimidazole compounds as c-Kit inhibitors | |
| KR101849143B1 (ko) | 트로포미오신 수용체 키나제(Trk) 억제제인 치환된 피라졸로[1,5-a]피리딘 | |
| JP6495285B2 (ja) | Ｔｎｆ活性のモジュレーターとしての縮合イミダゾール及びピラゾール誘導体 | |
| JP2024038447A (ja) | Ｅｈｍｔ２阻害剤としてのアミン置換複素環化合物及びその誘導体 | |
| US12213969B2 (en) | 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors | |
| CA2932008A1 (en) | Fused tricyclic benzimidazoles derivatives as modulators of tnf activity | |
| US7479558B2 (en) | Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives | |
| WO2017167994A1 (en) | Fused pentacyclic imidazole derivatives as modulators of tnf activity | |
| JP7767301B2 (ja) | チロシン受容体キナーゼ阻害剤を調製する方法 | |
| JP2019535812A (ja) | キナーゼ阻害剤としてのアミド化合物 | |
| EP3436458A1 (en) | Fused pentacyclic imidazole derivatives as modulators of tnf activity | |
| US20210292329A1 (en) | Methods of preparing indolinobenzodiazepine derivatives | |
| WO2024017227A1 (zh) | 取代的稠环大麻素受体化合物及其应用 | |
| AU2022392348A1 (en) | 15-pgdh inhibitor and use thereof | |
| JP2021011492A (ja) | ４Ｈ−ピリド［１，２−ａ］ピリミジン−４−オン化合物 | |
| WO2026019930A1 (en) | Compositions useful for modulating splicing | |
| WO2026019893A1 (en) | Compositions useful for modulating splicing | |
| NZ795530A (en) | Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof |